Jaguar Health (NASDAQ:JAGX) Share Price Crosses Above 50 Day Moving Average – What’s Next?

Jaguar Health, Inc. (NASDAQ:JAGX)’s stock price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.18 and traded as high as $1.19. Jaguar Health shares last traded at $1.14, with a volume of 309,156 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a report on Friday, September 13th.

Jaguar Health Stock Performance

The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.60 and a current ratio of 2.10. The firm’s 50 day moving average price is $1.18 and its 200-day moving average price is $4.59.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.84). The business had revenue of $2.72 million for the quarter. Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. Sell-side analysts forecast that Jaguar Health, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new stake in shares of Jaguar Health, Inc. (NASDAQ:JAGX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned approximately 0.51% of Jaguar Health as of its most recent SEC filing. 12.04% of the stock is owned by institutional investors.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.